MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
CEMI - Chembio Diagnostics Inc.
$2.44
0.01(0.41%)8:00:00 PM 10/21/2021
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for HIV and Syphilis, and Zika virus. It also develops tests for malaria, Dengue virus, chikungunya virus, ebola, lassa, marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. In addition, the company develops tests for a specific form of cancer, concussion, and bovine tuberculosis; and handheld optical analyzers for rapid diagnostic tests. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; Foundation for Innovative New Diagnostics to develop a POC fever panel assay for life-threatening acute febrile illnesses; AstraZeneca to develop a POC test for eosinophilic respiratory disease; and Shire Human Genetic Therapies, Inc. to develop a novel POC diagnostic test. It also has a strategic partnership with LumiraDx Limited to develop point-of-care diagnostic tests for the detection of the COVID-19 virus, and IgM and IgG antibodies on the LumiraDx and Chembio DPP platforms. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Summary:

  • Volatility is at a recent 2 week low. A recent low volatility of stock movement within a box range could trigger break through when activities pick up.
  • A moving average of short volume ratio is at a recent 2 week low. A lower short volume ratio could be a bullish signal.
Stock Statistics
MarketCap69.6M
PE Ratio
PEG Ratio-0.2
P/B2.6
P/S (ttm)1.8
Earning Growth (QoQ)
Revenue Growth (QoQ)
Short %11%
Held by Institutions %36%
1 Day Vol Adjusted Return0.2
1 Month Vol Adjusted Return-3.3
3 Month Vol Adjusted Return-4.5
6 Month Vol Adjusted Return-7.9
20 Days SMA Price ZScore-0.3
50 Days SMA Price ZScore-1.0
12 -26 Days PPO-2.1
1 Month Average Short Volume Ratio32.8
1 Day Volume Change ZScore-0.7
1 Month Daily Vol2.4
Related Topics
Peers

Stock news

    10/21/2021CEMI
    Chembio Diagnostics to Report Third Quarter 2021 Financial Results on November 4, 2021

    HAUPPAUGE, N.Y., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the third quarter of 2021 after the close of trading on Thursday, November 4, 2021. The company’s management team will host a corresponding conference call beginning at 4:30 p.m. Eastern Time on November 4, 2021. Investors interested in listening to the conference call ma

    09/22/2021CEMI
    Chembio Announces EUA Submission for DPP Respiratory Antigen Panel

    Test Provides Simultaneous Detection of Flu A, Flu B, and SARS-CoV-2HAUPPAUGE, N.Y., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the submission of an Emergency Use Authorization (EUA) application to the Food and Drug Administration (FDA) for the company’s DPP Respiratory Antigen Panel test system. The DPP Respiratory Antigen Panel test system is designed to provide simulta

    09/10/2021CEMI
    20 Stocks Moving in Friday's Pre-Market Session

    Gainers IVERIC bio, Inc. (NASDAQ: ISEE) rose 29.6% to $11.26 in pre-market trading. Iveric Bio recently reported inducement grants under Nasdaq Listing Rule 5635(c)(4). T2 Biosystems, Inc. (NASDAQ: TTOO) rose 25.8% to $1.09 in pre-market trading after the company announced its T2SARS-CoV-2 panel proved capable of detecting the Mu B.1.621 and Iota B.1.526 variants of the SARS-CoV-2 virus. Affirm Holdings, Inc. (NASDAQ: AFRM) rose 23.5% to $113.73 in pre-market trading after the company reported b

    08/30/2021CEMI
    Company News for Aug 30, 2021

    Companies in the news are: UI, CEMI, GAMB, BZ

    08/27/2021CEMI
    Why Chembio Diagnostics Shares Are Trading Higher Today

    Chembio Diagnostics Inc (NASDAQ: CEMI) is trading higher Friday after the company announced its launch of commercial distribution of SCOV-2 Ag Detect Rapid Test, a third party COVID-19 antigen assay. Chembio Diagnostics said product inventory is on-hand and immediately available for shipment to customers across the United States. The SCOV-2 Ag Detect Rapid Test provides results in 20 minutes from a nasal swab and requires no instrumentation. “We believe this product is an important addition to o